Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

8,713 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A MYCN-independent mechanism mediating secretome reprogramming and metastasis in MYCN-amplified neuroblastoma.
Zhang HF, Delaidelli A, Javed S, Turgu B, Morrison T, Hughes CS, Yang X, Pachva M, Lizardo MM, Singh G, Hoffmann J, Huang YZ, Patel K, Shraim R, Kung SHY, Morin GB, Aparicio S, Martinez D, Maris JM, Bosse KR, Williams KC, Sorensen PH. Zhang HF, et al. Among authors: patel k. Sci Adv. 2023 Aug 25;9(34):eadg6693. doi: 10.1126/sciadv.adg6693. Epub 2023 Aug 23. Sci Adv. 2023. PMID: 37611092 Free PMC article.
Epigenomic profiling of neuroblastoma cell lines.
Upton K, Modi A, Patel K, Kendsersky NM, Conkrite KL, Sussman RT, Way GP, Adams RN, Sacks GI, Fortina P, Diskin SJ, Maris JM, Rokita JL. Upton K, et al. Among authors: patel k. Sci Data. 2020 Apr 14;7(1):116. doi: 10.1038/s41597-020-0458-y. Sci Data. 2020. PMID: 32286315 Free PMC article.
The B7-H3-Targeting Antibody-Drug Conjugate m276-SL-PBD Is Potently Effective Against Pediatric Cancer Preclinical Solid Tumor Models.
Kendsersky NM, Lindsay J, Kolb EA, Smith MA, Teicher BA, Erickson SW, Earley EJ, Mosse YP, Martinez D, Pogoriler J, Krytska K, Patel K, Groff D, Tsang M, Ghilu S, Wang Y, Seaman S, Feng Y, Croix BS, Gorlick R, Kurmasheva R, Houghton PJ, Maris JM. Kendsersky NM, et al. Among authors: patel k. Clin Cancer Res. 2021 May 15;27(10):2938-2946. doi: 10.1158/1078-0432.CCR-20-4221. Epub 2021 Feb 22. Clin Cancer Res. 2021. PMID: 33619171 Free PMC article.
A GPC2 antibody-drug conjugate is efficacious against neuroblastoma and small-cell lung cancer via binding a conformational epitope.
Raman S, Buongervino SN, Lane MV, Zhelev DV, Zhu Z, Cui H, Martinez B, Martinez D, Wang Y, Upton K, Patel K, Rathi KS, Navia CT, Harmon DB, Li Y, Pawel B, Dimitrov DS, Maris JM, Julien JP, Bosse KR. Raman S, et al. Among authors: patel k. Cell Rep Med. 2021 Jul 21;2(7):100344. doi: 10.1016/j.xcrm.2021.100344. eCollection 2021 Jul 20. Cell Rep Med. 2021. PMID: 34337560 Free PMC article.
Pre-clinical investigation of astatine-211-parthanatine for high-risk neuroblastoma.
Makvandi M, Samanta M, Martorano P, Lee H, Gitto SB, Patel K, Groff D, Pogoriler J, Martinez D, Riad A, Dabagian H, Zaleski M, Taghvaee T, Xu K, Lee JY, Hou C, Farrel A, Batra V, Carlin SD, Powell DJ Jr, Mach RH, Pryma DA, Maris JM. Makvandi M, et al. Among authors: patel k. Commun Biol. 2022 Nov 17;5(1):1260. doi: 10.1038/s42003-022-04209-8. Commun Biol. 2022. PMID: 36396952 Free PMC article.
A proteogenomic surfaceome study identifies DLK1 as an immunotherapeutic target in neuroblastoma.
Weiner AK, Radaoui AB, Tsang M, Martinez D, Sidoli S, Conkrite KL, Delaidelli A, Modi A, Rokita JL, Patel K, Lane MV, Zhang B, Zhong C, Ennis B, Miller DP, Brown MA, Rathi KS, Raman P, Pogoriler J, Bhatti T, Pawel B, Glisovic-Aplenc T, Teicher B, Erickson SW, Earley EJ, Bosse KR, Sorensen PH, Krytska K, Mosse YP, Havenith KE, Zammarchi F, van Berkel PH, Smith MA, Garcia BA, Maris JM, Diskin SJ. Weiner AK, et al. Among authors: patel k. bioRxiv [Preprint]. 2024 Jan 7:2023.12.06.570390. doi: 10.1101/2023.12.06.570390. bioRxiv. 2024. Update in: Cancer Cell. 2024 Nov 11;42(11):1970-1982.e7. doi: 10.1016/j.ccell.2024.10.003 PMID: 38106022 Free PMC article. Updated. Preprint.
BPTF cooperates with MYCN and MYC to link neuroblastoma cell cycle control to epigenetic cellular states.
Felipe I, Martínez-de-Villarreal J, Patel K, Martínez-Torrecuadrada J, Grossmann LD, Roncador G, Cubells M, Farrell A, Kendsersky N, Sabroso-Lasa S, Sancho-Temiño L, Torres K, Martinez D, Perez JM, García F, Pogoriler J, Moreno L, Maris JM, Real FX. Felipe I, et al. Among authors: patel k. bioRxiv [Preprint]. 2024 Feb 12:2024.02.11.579816. doi: 10.1101/2024.02.11.579816. bioRxiv. 2024. PMID: 38405949 Free PMC article. Preprint.
Identification and Characterization of Chemotherapy-Resistant High-Risk Neuroblastoma Persister Cells.
Grossmann LD, Chen CH, Uzun Y, Thadi A, Wolpaw AJ, Louault K, Goldstein Y, Surrey LF, Martinez D, Calafatti M, Gerelus M, Gao P, Lee L, Patel K, Kaufman RS, Shani G, Farrel A, Moshitch-Moshkovitz S, Grimaldi P, Shapiro M, Kendsersky NM, Lindsay JM, Casey CE, Krytska K, Scolaro L, Tsang M, Groff D, Matkar S, Kalna JR, Mycek E, McDevitt J, Runbeck E, Patel T, Bernt KM, Asgharzadeh S, DeClerck YA, Mossé YP, Tan K, Maris JM. Grossmann LD, et al. Among authors: patel k, patel t. Cancer Discov. 2024 Dec 2;14(12):2387-2406. doi: 10.1158/2159-8290.CD-24-0046. Cancer Discov. 2024. PMID: 39083807
A proteogenomic surfaceome study identifies DLK1 as an immunotherapeutic target in neuroblastoma.
Hamilton AK, Radaoui AB, Tsang M, Martinez D, Conkrite KL, Patel K, Sidoli S, Delaidelli A, Modi A, Rokita JL, Lane MV, Hartnett N, Lopez RD, Zhang B, Zhong C, Ennis B, Miller DP, Brown MA, Rathi KS, Raman P, Pogoriler J, Bhatti T, Pawel B, Glisovic-Aplenc T, Teicher B, Erickson SW, Earley EJ, Bosse KR, Sorensen PH, Krytska K, Mosse YP, Havenith KE, Zammarchi F, van Berkel PH, Smith MA, Garcia BA, Maris JM, Diskin SJ. Hamilton AK, et al. Among authors: patel k. Cancer Cell. 2024 Nov 11;42(11):1970-1982.e7. doi: 10.1016/j.ccell.2024.10.003. Epub 2024 Oct 24. Cancer Cell. 2024. PMID: 39454577 Free article.
8,713 results